AQR Capital Management LLC Has $191.39 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AQR Capital Management LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 60.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 813,356 shares of the biopharmaceutical company’s stock after acquiring an additional 307,702 shares during the period. AQR Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $191,391,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ALNY. Larson Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 73 shares in the last quarter. R Squared Ltd bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $33,000. OFI Invest Asset Management acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Versant Capital Management Inc grew its holdings in shares of Alnylam Pharmaceuticals by 77.6% during the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 83 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 47 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $254.85 on Tuesday. The company’s 50 day simple moving average is $247.46 and its 200 day simple moving average is $255.63. The stock has a market capitalization of $33.15 billion, a price-to-earnings ratio of -117.44 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 1 year low of $143.50 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ALNY. Needham & Company LLC reissued a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research note on Friday, March 21st. HC Wainwright restated a “buy” rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Finally, Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $315.58.

Insider Buying and Selling

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,392 shares of company stock valued at $1,875,627 over the last 90 days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.